Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Live Streamed
On Demand
455 Views
Favorite
Facebook
Tweet
Print
Session: New Antimicrobials in the Pipeline
50 - Developing bispecific monoclonal antibody (mAb) therapies, gremubamab and AZD0292, targeted against Pseudomonas aeruginosa sponsored by AstraZeneca
Monday, October 20, 2025
8:36 AM - 8:48 AM
US ET
Location: B302-B304
Industry Presenter(s)
Tope Oyedele, MD (he/him/his)
Senior Medical Director
AstraZeneca
Gaithersburg, MD, United States
Slides
Disclosure(s):
Tope Oyedele, MD
: AstraZeneca: Employee, Stocks/Bonds (Public Company)
